XML 31 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)
0 Months Ended 3 Months Ended 12 Months Ended
Jan. 27, 2014
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Common stock, par value (in dollars per share)   $ 0.01us-gaap_CommonStockParOrStatedValuePerShare   $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Stock split, conversion ratio 0.0833us-gaap_StockholdersEquityNoteStockSplitConversionRatio1      
Share-based compensation arrangement by share-based payment award, expiration period   10 years    
Stock-based compensation   $ 114,000us-gaap_ShareBasedCompensation $ 331,000us-gaap_ShareBasedCompensation  
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options   500,000us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions    
Unvested stock options, unrecognized compensation expense weighted average recognition period   1 year 3 months 25 days    
Stock options, granted (in shares)   12,350us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 199,080us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross  
Stock options, fair value assumptions, risk free interest rate   1.61%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate    
Stock options, fair value assumptions, dividend yield   0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate    
Stock options, fair value assumptions, expected life   4 years 1 month 15 days    
Stock options, fair value assumptions, historical volatility rate   86.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate    
Common stock rights issued (in shares)   1,208,491tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights 115,432tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights  
Deferred revenue   1,121,000us-gaap_DeferredRevenueCurrent   1,035,000us-gaap_DeferredRevenueCurrent
Foreign currency translation adjustment   (34,000)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax 12,000us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax (50,000)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
Foreign currency transaction loss, realized (less than)   100,000us-gaap_ForeignCurrencyTransactionGainLossRealized 100,000us-gaap_ForeignCurrencyTransactionGainLossRealized  
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)   8,248,953us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 5,523,975us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount  
Accumulated Other Comprehensive Income        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Foreign currency translation adjustment   (34,000)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember
12,000us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember
(50,000)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember
Pharmacogenomic Services        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Deferred revenue   300,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_PharmacogenomicServicesMember
  300,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_PharmacogenomicServicesMember
Diagnostic Tools        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Deferred revenue   900,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_DiagnosticToolsMember
  700,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_DiagnosticToolsMember
Executive Officers        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options, unvested options, vesting period   3 years    
Common stock rights issued (in shares)   98,333tbio_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights
/ us-gaap_TitleOfIndividualAxis
= us-gaap_ExecutiveOfficerMember
   
Selling, General and Administrative Expenses        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation   $ 100,000us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember
$ 300,000us-gaap_ShareBasedCompensation
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember
 
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options, unvested options, vesting period   1 year    
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options, unvested options, vesting period   3 years